Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients – AGMT_GASTRIC-3.

Veröffentlicht vonadmin

Wöll, E, Thaler, J, Keil, F, Gruenberger, B, Hejna, M, Eisterer, W, Fridrik, MA, Ulmer, H, Trommet, V, Huemer, F, Weiss, L, Greil, R.

http://www.ncbi.nlm.nih.gov/pubmed/28982869